NeuroFront

What NeuroFront does

NeuroFront is a privately held biotechnology company founded in 2020 and headquartered in Pudong, China, that describes its mission as the acquisition, development, and commercialization of transformative neuroscience medicines. With 1-10 employees, the company operates at an early-stage scale and has not disclosed funding rounds, clinical assets, or commercial products in the available data. Its leadership consists of co-founders June Yan (CEO) and Gary Tong (CMO), with no additional management or scientific advisory team disclosed in the input.

The company's visible strategic activity centers on brain-computer interface (BCI) rather than purely pharmaceutical neuroscience. On 2026-03-27, NeuroFront signed a cooperation agreement with the Beijing-inaugurated NeuroFrontier BCI Institute, aligning the company with the Zhongguancun BCI industrial cluster that Beijing authorities are formalizing through supporting policies in Changping and the Beijing Economic-Technological Development Area. This positions NeuroFront within a government-coordinated ecosystem intended to commercialize BCI research, suggesting the company's near-term focus is on BCI-related development and collaboration rather than late-stage drug commercialization.

The business model is not articulated in the source material. No pricing model, go-to-market approach, customer segments, or revenue mechanics are disclosed. Given pre-clinical-stage signals (no products, no revenue, sub-10 headcount), the company is likely operating on a development-and-partnership model, with monetization contingent on future licensing, collaboration milestones, or product commercialization within the BCI and neuroscience verticals. The website (neurofrontrx.com) reinforces a therapeutics-oriented identity, while the BCI institute tie-up signals a parallel device-oriented direction that the company has not formally reconciled in public disclosures.

Name

NeuroFront

Website

https://neurofrontrx.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

NeuroFront is a privately held, early-stage biotechnology company founded in 2020 in Pudong, China, focused on acquiring, developing, and commercializing transformative neuroscience medicines. It has expanded into Beijing's BCI ecosystem via a 2026 cooperation agreement with the NeuroFrontier BCI Institute.

Ownership category

akta.pro rank

Product category

Neuroscience Therapeutics and BCI Systems

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Neuroscience therapeutics
• Brain-computer interface
• Neurological drug development
• BCI medical systems
• Neural rehabilitation devices

Headquarters

HQ city

Pudong

HQ country

China

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Core offering

NeuroFront is a clinical-stage biotechnology company focused on the acquisition, development, and commercialization of transformative neuroscience medicines. The company is also engaged in brain-computer interface (BCI) innovation, including invasive and non-invasive BCI systems, targeting medical rehabilitation, stroke treatment, sleep monitoring, and industrial safety applications.

Product overview

NeuroFront is associated with the NeuroFrontier BCI Institute, which was inaugurated by Beijing on March 27, 2026. The company is part of China's brain-computer interface ecosystem, showcasing 15 representative BCI innovation outcomes including invasive and non-invasive systems targeting medical rehabilitation, stroke treatment, sleep monitoring, and industrial safety applications. The source material does not provide detailed product names or specific product/service offerings beyond the general BCI research and development context.

Differentiator

Problem solved

Functional benefit

Products and services

• Invasive BCI Systems Brain-computer interface systems that use invasive neural signal acquisition methods, targeting medical applications such as rehabilitation and stroke treatment. Designed for healthcare providers and clinical research institutions.
• Non-invasive BCI Systems Brain-computer interface systems that acquire neural signals without surgical implantation, applied to sleep monitoring and industrial safety use cases. Suitable for healthcare monitoring, consumer wellness, and occupational safety applications.
• Transformative Neuroscience Medicines Therapeutic medicines targeting neurological conditions, developed through acquisition, in-house development, and commercialization. Aimed at healthcare providers and patients with neurological disorders.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• NeuroFrontier BCI InstitutecoreOthers · 27 March 2026Beijing officially inaugurated the NeuroFrontier BCI Institute on March 27 at the Brain-Computer Interface Innovation Development Forum. The institute is signing cooperation agreements with several companies to promote research commercialization. The city released plans for a Zhongguancun BCI industrial cluster while Changping and the Beijing Economic-Technological Development Area introduced supporting policies, establishing a multi-hub industrial ecosystem.

Recent moves2 records

Expansion highlights4 records

Direct peers

• Synchron: Synchron develops a stent-based BCI for patients with paralysis and is the most clinically advanced BCI competitor. NeuroFront’s BCI + rehabilitation overlap makes Synchron a directly relevant peer despite its different delivery modality.
• Neuralink: Neuralink is a high-profile implantable BCI company pursuing CNS applications including motor restoration and medical rehabilitation. It shares NeuroFront’s brain-computer-interface + neuroscience-medicines thesis and competes for the same regulatory and clinical narrative.
• MindMaze: MindMaze builds digital neurotherapeutics and BCI-based rehabilitation platforms for stroke and brain-injury recovery. It directly overlaps NeuroFront’s stroke-treatment and medical-rehabilitation use cases.
• Blackrock Neurotech: Blackrock Neurotech develops invasive and non-invasive BCI systems targeting medical and rehabilitation use cases. It is the most direct comparison to NeuroFront given NeuroFront’s BCI + neuroscience-medicines positioning inside the Beijing NeuroFrontier Institute.
• BrainCo: BrainCo is a Chinese BCI/neurotechnology company developing both invasive and non-invasive systems for education, rehabilitation, and wellness. It is the closest Chinese analogue to NeuroFront and operates in the same regional policy ecosystem that NeuroFront’s Beijing institute partnership taps into.

Emerging players

• Sage Therapeutics: Sage Therapeutics develops CNS therapeutics for depression, epilepsy, and neurology. Comparable as a small, neuroscience-focused biopharma working on transformative CNS medicines, similar to NeuroFront’s stated positioning.
• Paradromics: Paradromics is an early-stage implantable BCI company focused on high-data-rate neural interfaces. It is comparable to NeuroFront as a fellow emerging neurotechnology platform chasing clinical and CNS applications.

Broad incumbents

• Biogen: Biogen is a large CNS-focused biopharma with neurology, psychiatry, and rare-disease pipelines. While a different modality, it represents the commercial-scale CNS pharmaceuticals category that NeuroFront’s stated mission of ‘neuroscience medicines’ ultimately targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/neurofront-therapeutics-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroFront